DERMAGRAFT

FDA Premarket Approval P000036

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the dermagraft(r). The device is indicated for use in the treatment of full-thickness diabetic foot ulcers greater than six weeks duration which extend through the dermis, but without tendon muscle, joint capsule or bone exposure. Dermagraft(r) should be used in conjunction with standard wound care regimens and in patients that have adequate blood supply to the involved foot.

DeviceDERMAGRAFT
Generic NameDressing, Wound And Burn, Interactive
ApplicantSHIRE REGENERATIVE MEDICINE
Date Received2000-08-25
Decision Date2001-09-28
Notice Date2001-10-31
PMAP000036
SupplementS
Product CodeMGR 
Docket Number01M-0498
Advisory CommitteeGeneral & Plastic Surgery
Expedited ReviewNo
Combination Product Yes
Applicant Address SHIRE REGENERATIVE MEDICINE 11095 Torreyana Road san Diego, CA 92121
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P000036Original Filing
S018 2013-04-25 30-day Notice
S017 2013-04-24 30-day Notice
S016 2013-04-23 30-day Notice
S015
S014 2012-12-21 135 Review Track For 30-day Notice
S013 2012-06-29 30-day Notice
S012 2012-06-05 30-day Notice
S011 2012-04-23 135 Review Track For 30-day Notice
S010 2012-03-16 30-day Notice
S009 2012-03-16 30-day Notice
S008 2012-03-13 Normal 180 Day Track No User Fee
S007 2010-03-02 30-day Notice
S006 2008-10-31 30-day Notice
S005
S004
S003 2003-11-17 Special (immediate Track)
S002 2002-03-05 Special (immediate Track)
S001

© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.